Linklaters advises STADA on the acquisition of a European consumer healthcare portfolio from Sanofi

Linklaters has again advised STADA on the acquisition of established and leading local consumer healthcare brands from Sanofi. STADA is thereby expanding its portfolio in European markets including Belgium, Germany, Hungary, Spain, the UK and Sweden.

In Germany, the company will assume responsibility for the entire range of the well-known Antistax brand for venous disorders in the future. The transaction also includes other European brands such as Omnivit vitamins and the allergy eye drops Lomudal and Opticrom. In addition, the acquired portfolio includes the two painkillers AAS and Dolalgial, as well as Bila-Git for gallbladder complaints.

Linklaters had previously advised STADA on the acquisition of a European consumer healthcare portfolio of 16 brands from Sanofi in 2021. Linklaters advised with an international and cross-practice team led by Dr Tim Johannsen-Roth (Partner, Corporate/M&A, Düsseldorf), Sebastian Klingen (Counsel, Corporate/M&A, Düsseldorf) and Louis Prades (Managing Associate, Corporate/M&A, Paris). Dr Jana Hager (Partner, Public Commercial Law, Berlin) led the advice on the regulatory issues of the EU healthcare market with an integrated team.

Linklaters offices in Düsseldorf, Frankfurt, Brussels, Berlin, Paris, London and Madrid were involved in the transaction.